4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Repligen Corporation (RGEN) operates in the Medical Instruments & Supplies industry and is headquartered in Waltham, United States with about 2,000 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, RGEN reported $738M in revenue and $49M in net income.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Interactive charts & full statements → Open the RGEN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $738M | $634M | $632M | $802M |
| Gross Profit | $386M | $275M | $278M | $456M |
| Operating Income (EBIT) | $42M | ($32M) | $17M | $196M |
| Net Income | $49M | ($26M) | $36M | $186M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $194M | $198M | $189M | $182M | $169M |
| Gross Profit | $108M | $104M | $100M | $91M | $91M |
| Operating Income (EBIT) | $17M | $16M | $13M | $6M | $9M |
| Net Income | $8M | $13M | $15M | $15M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $2.9B | $2.8B | $2.8B | $2.5B | — |
| Total Liabilities | $844M | $857M | $866M | $621M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RGEN viewer.
About TickerBase · Data methodology & sources